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Abstract: Nanoparticles can be considered as a useful tool for improving properties of poorly soluble
active ingredients. Hydrochlorothiazide (Class IV of the Biopharmaceutical Classification System)
was chosen as a model compound. Antisolvent precipitation-solvent evaporation and emulsion
solvent evaporation methods were used for preparation of 18 samples containing hydrochlorothiazide
nanoparticles. Water solutions of surfactants sodium dodecyl sulfate, Tween 80 and carboxymethyl
dextran were used in mass concentrations of 1%, 3% and 5%. Acetone and dichloromethane were
used as solvents of the model compound. The particle size of the prepared samples was measured
by dynamic light scattering. The selected sample of hydrochlorothiazide nanoparticles stabilized
with carboxymethyl dextran sodium salt with particle size 2.6 nm was characterized additionally by
Fourier transform mid-infrared spectroscopy and scanning electron microscopy. It was found that
the solubility of this sample was 6.5-fold higher than that of bulk hydrochlorothiazide.
Keywords: hydrochlorothiazide; nanoparticles; dynamic light scattering; infrared spectroscopy;
scanning electron microscopy; solubility
1. Introduction
Hydrochlorothiazide (HCTZ, Figure 1), 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-
7-sulfonamide 1,1-dioxide, is a thiazide diuretic that is frequently used in antihypertensive therapy
in combination with antihypertensive agents. HCTZ affects the distal renal tubular mechanism of
electrolyte reabsorption: it increases excretion of sodium and chloride ions [1]. Due to this increased
excretion, it increases diuresis. HCTZ is not a first choice drug for hypertension treatment of patients
with diabetes mellitus because of metabolic side effects. HCTZ can cause hyperglycaemia; it can
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worsen glucose tolerance and cause hypercholesterolemia [2]. It is questionable whether HCTZ
nanoparticles (NPs) would have less adverse effects in a range of metabolic side effects. Metabolic side
effects of HCTZ are dose-dependent [3–7]. It can be stated that the best balance between effectiveness
and side effects is obtained with much smaller doses [8]. This fact was connected with hypokalemia
associated with high administrated doses of thiazides (up to 150 mg/day of HCTZ) [8]. Drug NPs
have been prepared to provide a possibility of treatment with a lower, but still therapeutic dose [9].
HCTZ belongs to Class IV of the Biopharmaceutical Classification System (BCS) [10]. Drugs of the
mentioned class are characterized by poor water solubility and low permeability; this means they are
problematic from the point of view of oral bioavailability [11]. Some nanonized drug substances have
been used in human treatment. Doses of nanodrugs can be lower than doses of bulk drugs, which
results in a lower pill burden [6,12].
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approaches of NPs preparation: bottom-up and top-down. Top-down techniques are based on milling 
or high-pressure homogenization. The bottom-up approach is mainly based on precipitation [12,17,18]. 
This approach was used in this study. 
Polar and nonpolar solvents were used in this investigation; therefore, the exact principle of the 
applied solvent evaporation method is dependent on the water-based system, including or not an 
aqueous miscible organic solvent. Polar acetone and nonpolar dichloromethane were chosen as the 
most suitable solvents for easy dissolution of HCTZ; so two different possible mechanisms were used 
for the NP synthesis. When HCTZ is dissolved in acetone and then mixed with water containing a 
stabilizer, NPs are formed spontaneously and immediately upon mixing. This method can be called 
antisolvent precipitation-solvent evaporation, and the procedure is in principle similar to the 
evaporative precipitation into aqueous solution [19,20] and the liquid antisolvent precipitation [21]. 
When HCTZ is dissolved in dichloromethane and then mixed with water containing stabilizers, an 
emulsion (o/w type) is formed; HCTZ is clustered by the excipient, which results in the encapsulation 
of HCTZ into nano-vesicula. This combination of emulsification and solvent evaporation in NP 
synthesis is called emulsion solvent evaporation [22,23]. 
2. Results and Discussion 
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surfactants. Three water solutions of 1%, 3% and 5% mass concentration were prepared. HCTZ was 
solved in dichloromethane (Series 1, 3, 5) as a non-polar solvent, and acetone (Series 2, 4, 6) as a polar 
solvent. Drug solution was added to the solution of excipient under continuous stirring. Organic 
solvent was evaporated in an ultrasonic bath that was used as a source of complementary energy for 
NPs preparation. The combination of all excipients with HCTZ provided 18 samples, see Table 1. All 
prepared samples were measured by dynamic light scattering [26], i.e., the particle size and values of 
polydispersity index were determined (see Table 1). The suitability of the used surfactant and the 
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The aim of this study was the preparation of stabilized HCTZ NPs via antisolvent precipitation
with the following solubility experiment. It was supposed that HCTZ NPs would have improved
bioavailability (some HCTZ nanoformulations were published recently [13–16]). There are two main
approaches of NPs preparation: bottom-up and top-down. Top-down techniques are based on milling
or high-pressure homogenization. The bottom-up approach is mainly based on precipitation [12,17,18].
This approach was used in this study.
Polar and nonpolar solvents were used in this investigation; therefore, the exact principle of
the applied solvent evaporation method is dependent on the water-based system, including or not
an aqueous miscible organic solvent. Polar acetone and nonpolar dichloromethane were chosen
as the most suitable solvents for easy dissolution of HCTZ; so two different possible mechanisms
were used for the NP synthesis. When HCTZ is dissolved in acetone and then mixed with water
containing a stabilizer, NPs are formed spontaneously and immediately upon mixing. This method
can be called antisolvent precipitation-solvent evaporation, and the procedure is in principle similar to
the evaporative precipitation into aqueous solution [19,20] and the liquid antisolvent precipitation [21].
When HCTZ is dissolved in dichloromethane and then mixed with water containing stabilizers,
an emulsion (o/w type) is formed; HCTZ is clustered by the excipient, which results in the
encapsulation of HCTZ into nano-vesicula. This combination of emulsification and solvent evaporation
in NP synthesis is called emulsion solvent evaporation [22,23].
2. Results and Discussion
Based on the pilot screening [24,25], excipients such as sodium dodecyl sulfate (Series 1, 2),
Tween 80 (Series 3, 4) and carboxymethyl dextran sodium salt (Series 5, 6) were chosen from the
group of surfactants. Three water solutions of 1%, 3% and 5% mass concentration were prepared.
HCTZ was solved in dichloromethane (Series 1, 3, 5) as a non-polar solvent, and acetone (Series 2, 4, 6)
as a polar solvent. Drug solution was added to the solution of excipient under continuous stirring.
Organic solvent was evaporated in an ultrasonic bath that was used as a source of complementary
energy for NPs preparation. The combination of all excipients with HCTZ provided 18 samples, see
Table 1. All prepared samples were measured by dynamic light scattering [26], i.e., the particle size
and values of polydispersity index were determined (see Table 1). The suitability of the used surfactant
and the organic solvent was analyzed.
Molecules 2016, 21, 1005 3 of 8
Table 1. Composition of samples (dichloromethane Series 1, 3, 5; acetone Series 2, 4, 6), concentration
(%) of individual excipients in water samples relative to hydrochlorothiazide, particle size (nm)
and polydispersity index (PDI) of hydrochlorothiazide samples expressed as mean ± SD (n = 5
independent measurements). (SDS = sodium dodecyl sulfate, TW = Tween 80, DCM = dichloromethane,
CMD = carboxymethyl dextran sodium salt, AC = acetone, n.d. = immeasurable due to crystallization)
Sample Excipient/Concentration (%) Particle Size (nm) PDI
1a SDS/DCM/1 24.5 ± 3.6 0.654 ± 0.073
1b SDS/DCM/3 102.2 ± 17.6 0.384 ± 0.021
1c SDS/DCM/5 21.0 ± 1.2 0.356 ± 0.011
2a SDS/AC/1 9.6 ± 0.4 0.302 ± 0.014
2b SDS/AC/3 4.2 ± 0.6 0.300 ± 0.027
2c SDS/AC/5 7.6 ± 1.2 0.271 ± 0.012
3a TW/DCM/1 10.5 ± 0.5 0.177 ± 0.020
3b TW/DCM/3 13.6 ± 0.7 0.189 ± 0.008
3c TW/DCM/5 n.d. n.d.
4a TW/AC/1 10.2 ± 0.1 0.154 ± 0.007
4b TW/AC/3 9.3 ± 0.3 0.128 ± 0.057
4c TW/AC/5 9.9 ± 0.1 0.157 ± 0.010
5a CMD/DCM/1 107.0 ± 51.4 0.396 ± 0.025
5b CMD/DCM/3 221.5 ± 28.5 0.470 ± 0.034
5c CMD/DCM/5 2.6 ± 0.2 0.212 ± 0.140
6a CMD/AC/1 493.2 ± 155.9 0.368 ± 0.075
6b CMD/AC/3 510.7 ± 33.7 0.396 ± 0.055
6c CMD/AC/5 2.8 ± 1.2 0.312 ± 0.040
The investigated particles showed good particle size stability throughout the light scattering
measurements, except for sample 3c that could not be measured due to crystallization of HCTZ.
In the course of the measurements, no significant deviations from the mean values of particle size,
which could be a result of possible sample ageing, were observed. In addition, a regular visual
check of the samples showed no changes in the sample structure, which was confirmed by the
reproducible data obtained by the light scattering method. NPs of size >100 nm were prepared in
the case of sodium dodecyl sulfate and carboxymethyl dextran sodium salt in combination with
dichloromethane (samples 1b, 5a, 5b) and carboxymethyl dextran sodium salt in combination with
acetone (samples 6a, 6b). On the other hand, carboxymethyl dextran sodium salt in 5% concentration in
combination with dichloromethane or acetone formed samples with the smallest particle sizes (2.6 nm
of sample 5c and 2.8 nm of sample 6c). Sodium dodecyl sulfate in combination with dichloromethane
provided particle size near 20 nm (samples 1a and 1c). Other prepared samples contained NPs in the
size range from 4.2 to 13.6 nm, mostly near 10 nm.
The dispersity is a measure/degree of the homogeneity/heterogeneity of sizes of particles in a
mixture/system. The uniformity of dispersed systems is expressed as polydispersity index (PDI), see
Table 1. Low PDI values demonstrate narrow size distribution and the uniformity of samples contrary
to PDI ≈ 1, which indicates that samples that have a very broad size distribution, may contain large
particles or aggregates and are not suitable for measurements [27,28]. In the prepared NPs of HCTZ,
PDI values ranged from 0.128 to 0.396, when the samples 1a and 5b (with PDI values 0.654 and 0.470)
were eliminated.
Sample 5c with the smallest particle size and low PDI, where HCZT was stabilized with 5%
carboxymethyl dextran sodium salt, was chosen for additional characterization and solubility test.
Figure 2 illustrates the Fourier transform mid infrared (FT-MIR) spectra of the starting bulk HCTZ,
carboxymethyl dextran sodium salt and HCTZ NPs stabilized with the excipient and thus verifies
the composition of sample 5c. Scanning electron microscopy (SEM) shows bulk HCZT, see Figure 3A,
while Figure 3B represents an SEM image showing the surface structure and the morphology of
sample 5c. The surface and structure of nanoparticles were uniform with no roughness.
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The s lubil ty of bulk HCTZ (as a control sampl ) and HCTZ NPs (sample 5c) was tested;
the resul s of is investigation ar presented in Table 2, where the concentrations of HCTZ NPs
diss lved in water with pH 6 were det rmined by HPLC in comparison with bulk HCTZ. The dissolved
amount of bulk HCTZ was 16.6 µg/mL, while that of HCTZ NPs was 107.9 µg/mL, i.e., the application
of NPs led to a significant, 6.5-fold increase of the solubility of HCTZ.
Table 2. Results of dissolution test.
Sample HPLC Determined Conc. (µg/mL) R
bulk HCTZ (control sample) 16.6 –
HCTZ NPs (sample 5c) 107.9 6.5
Water soluble, biodegradable, biocompat ble a d nontoxic carboxymethyl dextran has been
widely used as a stabilizer and a nanocarrier for drug delivery [29–36]. Based on the experiments,
it can be stated that carboxymethyl dextran sodium salt can be considered as a versatile stabilizer
for a variety of drugs from classes II–IV of the Biopharmaceutical Classification System, for example,
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lipophilic steroids [24], highly hydrophilic risedronate sodium [18], basic cimetidine [37], acid
candesartan cilexetil and calcium salt of atorvastatin [25]. In general, it provided stable NP samples
with narrow particle size distribution in concentrations of 3% and 5% in dichloromethane rather
than in acetone [17,24,25,37]. This may be connected with properties of non-polar dichloromethane
(with dipole moment 1.60 D in contrast to polar aprotic acetone with dipole moment 2.88 D [38]) and
hydrophilic charged polymeric carboxymethyl dextran sodium salt and their (non)bonding interactions
with used molecules of drugs [30–34]. Despite its toxicity, dichloromethane has been one of the most
widely used solvents of drugs of intrinsic emulsified phase [29,39] dispersed in aqueous solution of
carboxymethyl dextran sodium salt. The different mechanisms of generation of NPs in comparison with
the antisolvent precipitation process in the presence of polar acetone seems to be another important
parameter affecting the particle size and the homogeneity of the samples. Nevertheless, it can be
stated that the “net” formed by 5% concentration of carboxymethyl dextran sodium salt prevents
aggregation/agglomeration of drug substance particles.
3. Experimental Section
3.1. General Procedure for Preparation of Nanoparticles
The model compound hydrochlorothiazide (HCTZ) and the excipients sodium dodecyl
sulfate, Tween 80 and carboxymethyl dextran sodium salt were purchased from Sigma-Aldrich
(St. Louis, MO, USA). All compounds were of analytical grade. H2O-HPLC-Mili-Q Grade was used as
a solvent of the excipients. Each excipient (0.1, 0.3 or 0.5 g) was dissolved in water (10 mL), and three
solutions with mass concentrations 1%, 3% and 5% were prepared. HCTZ (0.1 g) was dissolved
in dichloromethane or acetone (10 mL), i.e., 1% solutions were prepared. The solution of HCTZ in
dichloromethane/acetone was slowly dropped (2 mL/min) to the aqueous solutions of excipients, and
the solutions were stirred at 600 rpm for 15 min at 25 ◦C, after which the mixtures were transferred to
the ultrasonic bath in the fume chamber, where they were mixed again for 20 min for homogenization
of the samples. Finally, the solvent was evaporated.
3.2. Particle Size Measurement
The particle size was determined using a Brookhaven dynamic light scattering system BI 9000
(Brookhaven Instruments Corporation, Holtsville, NY, USA) with a goniometer SM-200 and an argon
gas laser (Lexel 95, wavelength 514.5 nm). Scattered intensity was registered at scattering angle 90◦
and temperature 25 ◦C. All the samples were dispersed by sonication and additionally filtered directly
before the measurement through syringe filters with 0.45 µm pore size to remove mechanical impurities.
Five independent recordings of the autocorrelation function were done for each investigated excipient
concentration. The particle size was calculated from the translational diffusion coefficient using the
Stokes-Einstein formula. The translational diffusion coefficient was obtained based on the cumulant
expansion of the autocorrelation function up to the second cumulant. The presented particle sizes
are reported as the mean values taken of the set of five independent measurements. The results are
summarized in Table 1.
3.3. FT-IR Analysis
Fourier transform mid infrared (FT-MIR) spectra (Figure 2) were measured for confirmation of the
sample composition. The attenuated total reflectance (ATR) technique was used with a diamond crystal.
FT-MIR spectra were recorded by a Nicolet 7000 FT-IR spectrometer (Thermo Scientific, West Palm
Beach, FL, USA) in the range 4000–400 cm−1 with the resolution of 4 cm−1 and 32 scans.
3.4. Scanning Electron Microscopy
The morphology of the sample was studied using scanning electron microscopy (SEM).
The sample was attached to a microscopic glass, dried at 25 ◦C and then sputter-coated with thin film
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of gold. An electron microscope Quanta 450FEG (FEI, Hillsboro, OR, USA) was used for imaging of
the sample at the following working conditions: accelerating voltage 10.0 kV, working distance 8.0 mm
and probe current 100 mA. Structures of the samples are illustrated in Figure 3.
3.5. Solubility Test
Two beakers filled with 10 mL of phosphate buffer (pH 6) were placed on magnetic stirrers and
tempered to 36 ◦C [40–42]. Dry powders of bulk HCTZ or sample 5c were separately added to beakers
with buffer under continuous stirring (250 rpm). The beakers were covered by Parafilm®. When the
turbidity occurred, the content of the beaker was stirred for additional 24 h. If the turbidity did not
disappear, the samples were centrifuged and analyzed. Analysis of samples was performed using
a high performance liquid chromatograph Agilent 1200 Series (Agilent Technologies, Santa Clara,
CA, USA) equipped with a DAD, a quarter pump, and an automatic injector. The HPLC separation
process was monitored and evaluated by the ChemStation software. A chromatographic column
Gemini 5 µm C6-Phenyl 110A, 4.6 mm × 250 mm (Phenomenex®, Torrance, CA, USA) was used.
Isocratic elution by a mixture of MeOH p.a. (35%) and formic buffer (pH 4.0; 65%) as a mobile phase
was used. The total flow of the column was 1.0 mL/min, injection 10 µL, column temperature 40 ◦C,
and sample temperature 22 ◦C. The detection wavelength of 273 nm was chosen. The retention time of
HCTZ was 4.19± 0.05 min, the limit of detection (LOD) was 0.01 µg/mL, and the limit of quantification
(LOQ) of HCTZ was 0.04 µg/mL. The results are presented in Table 2.
4. Conclusions
Eighteen samples of HCTZ NPs were prepared by the antisolvent precipitation-solvent
evaporation and the emulsion solvent evaporation techniques. Three different excipients were used
as stabilizers in 1%, 3%, and 5% aqueous mass concentration. Dynamic light scattering was used for
particle size analysis. The polydispersity index (PDI) was determined. Low PDI values of the samples
confirmed narrow size distribution and the uniformity of the prepared systems. Sample 5c of HCTZ
NPs stabilized with 5% concentration of carboxymethyl dextran sodium salt (particle size 2.3 nm,
PDI 0.212) was chosen as the sample with the smallest particle size for following characterization and
analysis. SEM was used for surface identification, and FT-MIR spectroscopy was used for verification
of the sample composition. Finally, the solubility test confirmed the enhanced solubility of HCTZ NPs
in comparison with the solubility of bulk HCTZ (6.5-fold higher).
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